New Alzheimer's drug AK152 enters first human safety tests
NCT ID NCT07301502
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tests a new drug called AK152 in healthy volunteers and people with Alzheimer's disease. The main goal is to check if it is safe and tolerable, and to see how the body processes it. The study is small and early-stage, so it will not prove whether the drug works for Alzheimer's.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK152
- What this could lead to
- If successful, this could point toward a new treatment option for Alzheimer's disease that may help control symptoms or slow progression.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not effectiveness. It is small and may not show any benefit. Side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Frist Affiliated Hospital of USTC
Hefei, Anhui, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your brain help unlock Alzheimer's secrets?
- Can a gene therapy clear the toxic tau tangle in Alzheimer's?
- Can a new drug tame Alzheimer's? early trial aims to find out
- A scan that sees Alzheimer's tangles? trial puts tau tracer to the test
- Can a pill clear the toxic proteins behind Alzheimer's?
- A light switch for better sleep? Alzheimer's trial tests wireless circadian lighting